Immune Design's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Immune Design (IMDZ) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Peer Data As of Q1 2018
Competitors
178
Peer Group Market Share
100.00 %
Revenue Growth Y/Y
-1.86 %
Net Margin
-2,857.35 %
Key Findings: Immune Design vs Its Competitors
- TTM: Trailing 12-month revenue of 2M vs -M combined for its competitors (100.0% combined share).
- Trending: Latest-quarter revenue run-rate is decelerating (-13.3% annualized vs trailing 12 months).
- Peer revenue share: Immune Design accounted for 100.0% of combined revenue among its tracked peer group, up from 100.0% a year earlier.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
IMDZ Sales vs. its Competitors, Q1 2018
Immune Design generated 100.00 % of the combined sales of its peer group, up from 100.00 % a year earlier.
API endpoints for this dataset
https://api.csimarket.com/api/v1/companies/IMDZ/competitors
https://api.csimarket.com/api/v1/companies/IMDZ/relationships
https://api.csimarket.com/api/v1/companies/IMDZ/similar
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Connect Your AI Assistant
For context: the Major Pharmaceutical Preparations industry grew revenue 8.9% year over year, combined, vs -1.9% for Immune Design. Immune Design's share of combined industry revenue moved from 0.00% to 0.00%, a gain of 0.00 percentage points.
Immune Design's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Immune Design Corp. | - | No | No | No |
| High-Confidence Competitors (131) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
IMDZ Stock Performance relative to its Competitors
IMDZ
Competitors (weighted)
Percent change over the selected range
IMDZ Stock Performance relative to High-Confidence Competitors
IMDZ
High-Confidence Competitors (equal-weighted, 138)
Percent change over the selected range
Immune Design's Competitors Named by the Company
Competitive relationships identified from Immune Design reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Novartis International AG | Company report | 85% |
| AstraZeneca plc | Company report | 85% |
| Keros Therapeutics Inc | Company report | 85% |
| Janux Therapeutics Inc | Company report | 85% |
| Cytomx Therapeutics Inc | Company report | 85% |
| Eli Lilly And Company | Company report | 85% |
| Gilead Sciences Inc | Company report | 85% |
| Pfizer Inc. | Company report | 85% |
| Greenwich Lifesciences Inc | Company report | 85% |
| Bayer AG | Company report | 85% |
| Marker Therapeutics inc | Company report | 85% |
| Mirati Therapeutics Inc | Company report | 85% |
| Agentix Corp | Company report | 85% |
| Briacell Therapeutics Corp | Company report | 85% |
| Petvivo Holdings Inc | Company report | 85% |
| Propanc Biopharma Inc | Company report | 85% |
| Elanco Animal Health Incorporated | Company report | 85% |
| Allarity Therapeutics Inc | Company report | 85% |
| Sunshine Biopharma Inc | Company report | 85% |
| Oragenics Inc | Company report | 85% |
| Terns Pharmaceuticals Inc | Company report | 85% |
| Absci Corp | Company report | 85% |
| Vaxcyte Inc | Company report | 85% |
| Compass Therapeutics Inc | Company report | 85% |
| Protagonist Therapeutics inc | Company report | 85% |
| Cue Biopharma Inc | Company report | 85% |
| Qnity Electronics Inc | Company report | 85% |
| Mangoceuticals Inc | Company report | 85% |
| Sagimet Biosciences inc | Company report | 85% |
| Bnb Plus Corp | Company report | 85% |
| Northwest Biotherapeutics Inc | Company report | 85% |
| Calidi Biotherapeutics Inc | Company report | 85% |
| Tempest Therapeutics Inc | Company report | 85% |
| Puretech Health Plc | Company report | 85% |
| Voyager Therapeutics Inc | Company report | 85% |
| Mosaic Immunoengineering Inc | Company report | 85% |
| Maia Biotechnology Inc | Company report | 85% |
| Altimmune inc | Company report | 85% |
| Scynexis Inc | Company report | 85% |
| Candel Therapeutics Inc | Company report | 85% |
| Shattuck Labs Inc | Company report | 85% |
| Nuvation Bio Inc | Company report | 85% |
| Beone Medicines Ltd | Company report | 85% |
| Inhibrx Biosciences Inc | Company report | 85% |
| Coherus Oncology inc | Company report | 85% |
| Liminatus Pharma Inc | Company report | 85% |
| Curanex Pharmaceuticals Inc | Company report | 85% |
| Quantum si Incorporated | Company report | 85% |
| Bicara Therapeutics Inc | Company report | 85% |
| Nextcure Inc | Company report | 85% |
| Tenax Therapeutics Inc | Company report | 85% |
| Puma Biotechnology Inc | Company report | 85% |
| Chemomab Therapeutics Ltd | Company report | 85% |
| Trevi Therapeutics Inc | Company report | 85% |
| Personalis Inc | Company report | 85% |
| Enanta Pharmaceuticals Inc | Company report | 85% |
| Ernexa Therapeutics Inc | Company report | 85% |
| BGNE | Company report | 85% |
| Smartkem Inc | Company report | 85% |
| Can fite Biopharma Ltd | Company report | 85% |
| Abivax Sa | Company report | 85% |
| Agomab Therapeutics Nv | Company report | 85% |
| Palatin Technologies Inc | Company report | 85% |
| Gossamer Bio Inc | Company report | 85% |
| Nanoviricides inc | Company report | 85% |
| CHRO | Company report | 85% |
| Invivyd Inc | Company report | 85% |
| Bright Minds Biosciences Inc | Company report | 85% |
| Akero Therapeutics Inc | Company report | 85% |
| Sonnet Biotherapeutics Holdings Inc | Company report | 85% |
| Nascent Biotech Inc | Company report | 85% |
| Iovance Biotherapeutics inc | Company report | 85% |
| Vaccinex Inc | Company report | 85% |
| Silexion Therapeutics Corp | Company report | 85% |
| Mural Oncology Plc | Company report | 85% |
| Instil Bio Inc | Company report | 85% |
| Pelthos Therapeutics Inc | Company report | 85% |
| Boehringer Ingelheim GmbH | Company report | 85% |
| Dynavax Technologies Corporation | Company report | 85% |
| Invo Fertility Inc | Company report | 85% |
| Actuate Therapeutics Inc | Company report | 85% |
| Dupont De Nemours Inc | Company report | 85% |
| Pyxis Oncology Inc | Company report | 85% |
| NAYA | Company report | 85% |
| Optinose Inc | Company report | 85% |
| INVO | Company report | 85% |
| Cell Source Inc | Company report | 85% |
| Kiromic Biopharma Inc | Company report | 85% |
| Coya Therapeutics Inc | Company report | 85% |
| Ayala Pharmaceuticals Inc | Company report | 85% |
| Entegris Inc | Company report | 85% |
| Elicio Therapeutics Inc | Company report | 85% |
| Gridai Technologies Corp | Company report | 85% |
| ENTO | Company report | 85% |
| Skye Bioscience Inc | Company report | 85% |
| Cidara Therapeutics Inc | Company report | 85% |
| Vincerx Pharma Inc | Company report | 85% |
| Macrogenics Inc | Company report | 85% |
| Gri Bio Inc | Company report | 85% |
| Spyre Therapeutics Inc | Company report | 85% |
| Vaxxinity Inc | Company report | 85% |
| Atreca inc | Company report | 85% |
| Sutro Biopharma Inc | Company report | 85% |
| Immunome Inc | Company report | 85% |
| Twist Bioscience Corporation | Company report | 85% |
| Lineage Cell Therapeutics Inc | Company report | 85% |
| Ridgeback Biotherapeutics LP | Company report | 85% |
| Kronos Bio Inc | Company report | 85% |
| Corbus Pharmaceuticals Holdings Inc | Company report | 85% |
| Cytokinetics Incorporated | Company report | 85% |
| Agile Therapeutics Inc | Company report | 85% |
| Arbutus Biopharma Corp | Company report | 85% |
| Centessa Pharmaceuticals Plc | Company report | 85% |
| Agios Pharmaceuticals Inc | Company report | 85% |
| Biorestorative Therapies Inc | Company report | 85% |
| Ngm Biopharmaceuticals Inc | Company report | 85% |
| Immutep Limited | Company report | 85% |
| Seagen Inc | Company report | 85% |
| Novavax inc | Company report | 85% |
| Theriva Biologics inc | Company report | 85% |
| Enveric Biosciences Inc | Company report | 85% |
| Sellas Life Sciences Group Inc | Company report | 85% |
| Better Therapeutics Inc | Company report | 85% |
| Carisma Therapeutics Inc | Company report | 85% |
| Palisade Bio Inc | Company report | 85% |
| Essa Pharma inc | Company report | 85% |
| Morphic Holding inc | Company report | 85% |
| Scholar Rock Holding Corp | Company report | 85% |
| Aim Immunotech Inc | Company report | 85% |
| Cytodyn inc | Company report | 85% |
| Vanda Pharmaceuticals Inc | Company report | 85% |
| Anavex Life Sciences Corp | Company report | 85% |
| Igm Biosciences Inc | Company report | 85% |
| Bio techne Corp | Company report | 85% |
| Achieve Life Sciences Inc | Company report | 85% |
| Urogen Pharma Ltd | Company report | 85% |
| Alector Inc | Company report | 85% |
| Exagen Inc | Company report | 85% |
| Alx Oncology Holdings Inc | Company report | 85% |
| Lumos Pharma Inc | Company report | 85% |
| Viatris Inc | Company report | 85% |
| Medicines Co | Company report | 85% |
| Vertex Inc | Company report | 85% |
| Editas Medicine Inc | Company report | 85% |
| Johnson and Johnson | Company report | 85% |
| Takeda Pharmaceutical Company Limited | Company report | 85% |
| Bristol myers Squibb Company | Company report | 85% |
| Gsk Plc | Company report | 85% |
| Regeneron Pharmaceuticals Inc | Company report | 85% |
| Incyte Corporation | Company report | 85% |
| Zoetis Inc | Company report | 85% |
| Sanofi | Company report | 85% |
| Tiziana Life Sciences Ltd | Company report | 85% |
| Affimed N v | Company report | 85% |
| Phibro Animal Health Corporation | Company report | 85% |
| Nektar Therapeutics | Company report | 85% |
| Xencor Inc | Company report | 85% |
| Biogen Inc | Company report | 85% |
| Fortress Biotech Inc | Company report | 85% |
| Teva Pharmaceutical Industries Limited | Company report | 85% |
| Abbott Laboratories | Company report | 85% |
| United Therapeutics Corporation | Company report | 85% |
| Amgen Inc | Company report | 85% |
| Bolt Biotherapeutics Inc | Company report | 85% |
| Humanigen Inc | Company report | 85% |
| Lianbio | Company report | 85% |
| Exelixis Inc | Company report | 85% |
| Nkarta Inc | Company report | 85% |
| Abbvie Inc | Company report | 85% |
| Bellicum Pharmaceuticals Inc | Company report | 85% |
| Galapagos Nv | Company report | 85% |
| Jazz Pharmaceuticals Plc | Company report | 85% |
| Myovant Sciences Ltd | Company report | 85% |
| Vertex Pharmaceuticals Inc | Company report | 85% |
| Baxter International Inc | Company report | 85% |
| Esperion Therapeutics Inc | Company report | 85% |
| Horizon Therapeutics Public Limited Company | Company report | 85% |
| Lexicon Pharmaceuticals Inc | Company report | 85% |
Competitor Evidence Detail
Company report basis, confidence, active dates and source counts for Immune Design's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.